Finerenone Added to RAS/SGLT2 Blockade for Chronic Kidney Disease in Alport Syndrome. Results of a Randomized Controlled Trial with Col4a3-/- Mice.

Zhihui ZhuKaroline At RosenkranzYoshihiro KusunokiChenyu Li Martin Klaus Oliver Gross Maria-Lucia Angelotti Giulia Antonelli Luigi Cirillo Paola Romagnani Nassim Bouteldja Alireza Vafaei Sadr Roman David Bülow Peter Boor Hans-Johachim Anders

Published in: Journal of the American Society of Nephrology : JASN (2023)

Experiments in mice suggest that triple RAS/SGLT2/MR blockade may substantially improve renal outcomes in Alport syndrome and possibly other progressive chronic kidney diseases due to synergistic effects on the glomerular and tubulointerstitial compartments.

Keyphrases

wild type
chronic kidney disease
high fat diet induced
case report
end stage renal disease
multiple sclerosis
magnetic resonance
insulin resistance
cancer therapy
metabolic syndrome
adipose tissue